MetaCap

Bambusa Therapeutics (BBTX) vs Inhibrx Biosciences (INBX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inhibrx Biosciences is the larger company by market cap ($1.02 billion vs $815.1 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%INBX-3.91%
+29%+12%-6%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%INBX-3.91%
+19%+7%-5%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus INBX key metrics
MetricBBTXINBX
Share price$16.00$68.97
Market cap$815.08M$1.02B
1-day change+2.89%-7.21%
YTD return—-12.70%
1-year return—-17.82%
EPS (TTM)$-1.73$-9.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.30M
Revenue growth (YoY)—+550.00%
Net income (latest FY)—$-140.06M
Operating margin—-10386.54%
Net margin—-10773.46%
52-week high$17.65$155.29
52-week low$13.60$57.30
Distance from 52-week high-9.35%-55.59%
Analyst consensus—none
Avg. price target upside—+286.65%
Average volume359.41K305.96K
Shares outstanding50.94M14.77M
Employees26109
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About Inhibrx Biosciences

INBX stock →

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

BBTX vs INBX FAQ

Which is bigger, Bambusa Therapeutics or Inhibrx Biosciences?

Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.02B compared with $815.08M for Bambusa Therapeutics (BBTX).

Are Bambusa Therapeutics and Inhibrx Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons